LinkedIn post on Regeneron’s Praluent pricing and market rolloutExcerpt from House Oversight document citing Exchange Act penalties and FCPA reference
Case Filed-34219House OversightOGE Fonn 278 (March 2014)
January 1, 20250p
Case File
d-34219House OversightOGE Fonn 278 (March 2014)
Date
January 1, 2025
Source
House Oversight
Reference
d-34219
Pages
0
Persons
0
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.